HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Akio Kaito, Masanori Tokunaga, Reo Sato, Takahiro Kinoshita, Department of Gastric Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Takeshi Kuwata, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Kohei Shitara, Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Takeshi Kuwata, Kohei Shitara, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Tetsuo Akimoto, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan
Tetsuo Akimoto, Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Author contributions: Kaito A and Kuwata T contributed equally to this work in study conception, study design, data acquisition, quality control of data and algorithms, and data analysis and interpretation; Kaito A contributed to statistical analysis and manuscript preparation; All authors contributed equally to manuscript editing and manuscript review.
Institutional review board statement: This study was approved by the Institutional Review Board of the National Cancer Center, Japan, No. 2017-164, approval date: Oct. 11, 2017.
Informed consent statement: Comprehensive informed consent including publication without personally identifiable information was obtained from all of the subjects prior to study enrollment. Thus, specified informed consent for this study is not required. The public document of this study was published on our website: https://www.ncc.go.jp/jp/about/research_promotion/study/list/2017-164.pdf. Informed consent statement could not be obtained because most of the participants were deceased.
Conflict-of-interest statement: The authors have no conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Takeshi Kuwata, MD, PhD, Doctor, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa 277-8577, Japan. email@example.com
Telephone: +81-4-71331111 Fax: +81-4-71300190
Received: April 13, 2019
Peer-review started: April 15, 2019
First decision: May 16, 2019
Revised: June 16, 2019
Accepted: June 26, 2019
Article in press: June 27, 2019
Published online: August 6, 2019